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S198 Poster Session Icell (pCD34) count of\10/mL after 4 days of F alone. In this studywe
present the results of efficacy and an estimate of cost of such a risk
adaptive strategy for autologous peripheral blood HPC collection.
42 patients with history of NHL orMMundergoing peripheral blood
HPCmobilization fromFebruary toDecember 2009were included in
the analysis. All patients received daily filgrastim for 4 days. Our risk
adaptive approach was to add P for those ‘at-risk’ patients, who on day
4 had a pCD34 count of\10/mL,with apheresis commencing the fol-
lowing morning. Morning administration of F and evening dosing of
Pwas continued daily in this group of ‘at-risk’ patients for up to amax-
imum of 4 days or until. 5 106 CD341 cells/kgwere collected. Re-
sults of consecutive patients who had peripheral blood HPC
mobilization were prospectively collected. A decision analytic model
was created to estimate the mean cost and effectiveness rates in pa-
tients who underwent mobilization with F versus F 1 P. 18 patients
were mobilized with F alone and 24 patients required F1 P. Admin-
istration of P was safe and no severe adverse events were recorded. Ad-
dition of P increased the pCD34 count by 6.8 fold with an average
total yield of 4.9  106 CD341 cells/kg. The frequency of poor mo-
bilization among F only and F1 P patients was 25% and 7% respec-
tively. The pooled average cost benefit for mobilization with F 1 P
may be up to $ 16,900 per patient and could potentially increase the
annual number of transplants by more than 18%. Following autolo-
gous stem cell infusion, days to neutrophil and platelet engraftments
were similar between the patients who mobilized HPC with F versus
F 1 P (p5 0.12). These results suggest that addition of P to F based
on a risk adaptive strategy significantly reduces the frequency of mo-
bilization failures and is also cost effective. Addition of P to F forHPC
mobilization has no significant impact on the neutrophil and platelet
engraftment.121
NEUTROPENIC ENTEROCOLITIS (NE) IN ADULT PATIENTS (PTS)
UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT):
IMPACT OF BOWEL WALL THICKNESS ON CLINICAL OUTCOMES
Jimenez, A.M.1, Vasoo, S.2, Maciejewski, J.1, Rich, E.S.1, Karmali, R.1,
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Background: NE is an acute, life-threatening condition character-
ized by transmural inflammation of the intestinal wall in severely
myelosuppressed patients. Although initially described in pediatric
leukemia pts it has increasingly been reported in adults with a variety
of malignant conditions and in the setting of immunosuppression
with HSCT. The aim of this retrospective study was to evaluate
the prognostic value of clinical and radiographic findings in HSCT
recipients diagnosed with NE.
Patients and Methods: Data from 264 HSCT recipients over a 5
year period was reviewed. 24 pts with a clinical diagnosis of NE
supported by the triad of fever, abdominal pain and neutropenia
with radiographic evidence of bowel wall thickening (BWT) were
identified. Degree of BWT by CT scan [mild (m): 3-6 mm, moderate
(M): 6-12 mm and severe (S). 12 mm] along with clinical character-
istics (age, sex, diagnosis, co-morbidities, type of transplant, condi-
tioning regimen and neutropenia length) were evaluated and
correlated with clinical outcomes [complicated (CNE) vs. non-
complicated (cNE)] andmortality. CNEwas defined as those who be-
came bacteremic with enteric flora, required ICU admission or died.
Results: 264 pts underwent a HSCT from 2004 to 2010. A total of
24 (9.1%) pts (average age 52.67 yrs, range 23 – 70yrs) were diag-
nosed with NE. 14 (58.3%) pts underwent an autologous HSCT
and 10 (41.7%) an allogeneic HSCT. Median BWT was 6 mm
(range 2 -15 mm). 11 (45.8%) pts had mBWT, 9 (37.5%) pts
MBWT and 3 (12.5%) pts SBWT. 13(54.2%) pts had cNE and 11
(45.2%) pts had CNE. 7(29.2%) pts required ICU admission and
3 (12.5%) pts died. Clinical characteristics had no impact onmorbid-
ity or mortality in our pt population. Degree of BWT failed to im-
pact mortality on univariate analysis (dead vs. alive: $ 3mm p 5
0.25, $ 6 mm p 5 0.48, $ 12 mm p 5 1.00), but the presence of
MBWT and SBWT ($ 6 mm) was associated with a higher rate
of CNE (CNE vs. cNE: $ 6 mm p 5 0.003 OR:30.0, 95 % CI2.6-342.7). BWT$ 6 mm highly correlated with CNE on multivar-
iate analysis (p 5 0.009 OR:31.5 [2.35-422.3]).
Conclusion: Clinical characteristics had no prognostic impact in
adult patients who developed neutropenic enterocolitis following
HSCT. Patients with moderate and severe bowel thickening have
a worse clinical outcome however this failed to predict mortality;
likely the result of a small sample size. Larger studies and develop-
ment of standardized criteria for bowel thickness measurement are
warranted.122
LONG-TERM FOLLOW-UP OF METASTATIC BREAST CANCER PATIENTS
RECEIVING HIGHLY PURIFIED AUTOLOGOUS CD341THY-11 HEMATO-
POIETIC STEM CELLS AFTER HIGH-DOSE CHEMOTHERAPY
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Cha, S.1, Weissman, I.L.3, Shizuru, J.A.1 1Stanford University, Stan-
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In the 1990’s high-dose chemotherapy (HDCT) with autologous
hematopoietic cell transplantation (auto-HCT) was considered
a promising, potentially curative treatment approach for patients
(pts) with advanced or metastatic breast cancer (MBC). When ran-
domized trials did not confirm a significant benefit of HDCT over
standard chemotherapy (CTx) enthusiasm for this therapy fell and
transplantation studies ended abruptly. Despite improvements in
overall survival (OS) due to better CTx, endocrine, and immunologic
agents, MBC remains an incurable disease. One potential reason for
the failure ofHDCTwith auto-HCT is the high rate of occult tumor
cell contamination (OTC) in bone marrow, and accordingly in mo-
bilized blood grafts. Here we report the long-term follow-up of 15
pts that underwent HDCT (cisplatin, cyclophosphamide, BCNU)
at our institution between 12/96 and 4/98. FACS-purified
CD341Thy11 hematopoietic stem cells (HSC) with no detectable
tumor contamination (detection level 1/106 cells) were used as
grafts. Of note, 4/15 leukapheresis products contained OTC prior
to sorting. Pts were a median age of 43 years (y), were treated for pri-
mary stage IV BC (n5 5), or relapsed BC (n5 10). Status of remis-
sion at HCT was CR in 47%, and PR and SD in each 26.5% of pts.
More than 12 years after the end of the study 33% pts are alive, 27%
in CR. Median progression-free survival (PFS) is 16 months (m), the
PFS rate at 3y is 47%, at 10y 27%, each. Median OS for the entire
group and for survivors is 120m and 160m, respectively. 5y and
10y OS rates are 60% and 47%, respectively. In comparison, of 78
pts given the same HDCT regimen but unmanipulated grafts, 9%
are alive, and 6% without disease, 71% died of their BC, 22% died
of other reasons, and 4% were lost to follow-up. Median PFS is
9m, and the PFS rates at 3, 5, and 10y are 18%, 11%, and 8%, respec-
tively. Median OS for the entire group was 26m, and 154m for the 7
survivors. OS rates at 3y, 5y and 10y were 39%, 25%, and 13%, re-
spectively. Even though pts numbers in the HSC group are small,
and may include a highly selected population, our data suggest that
infusion of a hematopoietic graft, devoid of OTC, may be critical
to prolong time to relapse, and increase the proportion of CR. We
believe HDCT could regain relevance within multimodal treatment
approaches, as a good remission and avoidance of relapse due to
OTC in the graft could serve as a foundation for treatment with
novel biological and small molecule agents.123
ADAPTIVE RANDOMIZATION FOR BMT CLINICAL TRIALS WITH BOTH
EFFICACY AND FUTILITY OUTCOMES
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Bone marrow transplant (BMT) clinical trials generally feature
fixed randomization schedules determined before patient accrue-
ment. Bayesian adaptive designs based on in-trial treatment
Poster Session I S199performance are more likely to randomize patients into more effica-
cious, less toxic and less futile treatment regimens. Our research fo-
cuses on Phase II clinical trials measuring both efficacy and futility,
where randomization is based on performance between the treat-
ment arms. Retrospective data on 373 autologous transplant patients
undergoing mobilization from the VCU Massey Cancer Center are
used to simulate two prospective clinical trials with adaptive random-
ization. The cohort consists of adult patients diagnosed with either
HD, MM or NHL, and were assigned by their treating physician
into one of four mobilization groups: prelixafor (P, n5 19), chemo-
therapy1GCSF (Chemo, n 5 96), GCSF alone (GCSF, n 5 222)
and prelixafor early intervention (PEI, n 5 36). The first study de-
fines success as attainment of at least 5x106 total CD341 cells/kg
in less than 5 days, with futility defined as failing to collect at least
2x106 total CD341 cells/kg. The second study defines success as at-
tainment of at least 5x106 total CD341 cells/kg, with futility defined
as needing at least 5 days for CD341 collection. Results for the both
studies using the two-outcome adaptive randomization methodol-
ogy are found in the Table, showing the various accruement points
at which the efficacy rate for the Chemo group is higher than that
for the other groups with probability 0.95 for Study 1 and 0.99 for
Study 2. Conclusions are reached before the planned end of both
studies, reducing the number of patients by 99 in Study 1 and 261
in Study 2, since a conventional study requires at least 320 patients.
Differences in outcomes and patient numbers between these two
studies illustrate the importance of stringent success and futility def-
initions. Querying this cohort using other clinically relevant out-
comes, cost or toxicity endpoints may alter both cohort size and
conclusions. As shown through example, Bayesian adaptive random-
ization has the potential to reduce the time needed to reach a study’s
conclusion and ultimately reduce the amount of resources needed to
conduct a trial.
Table 1. Total and group accruement when Chemo efficacy
rate conclusively exceeds other groupsTotal 154 Total 171 Total 221
Study 1 Chemo 95 Chemo 96 Chemo 96P 7 GCSF 53 PEI 23Total 33 Total 38 Total 59
Study 2 Chemo 8 Chemo 12 Chemo 32PEI 7 P 7 GCSF 9124
THE COST-EFFECTIVENESS OF PLERIXAFOR PLUS G-CSF FOR STEM CELL
MOBILIZATION IN PATIENTS WITH DIFFUSE LARGE B-CELL NON-HODG-
KIN LYMPHOMA (DLBCL)
Kymes, S.M., Gregory, M., Lambert, D.L., Carson, K.R., Pusic, I.,
DiPersio, J.F. Washington University School of Medicine, St. Louis,
MO; Washington University School of Medicine, St. Louis, MO; Wash-
ington University, St. Louis, MO
Purpose: We conducted an economic evaluation of the cost-utility
of using Plerixafor with G-CSF (G1P) for stem cell mobilization
in patients with diffuse large B-cell non-Hodgkin Lymphoma
(DLBCL) versus using G-CSF (G) alone.
Methods: A decision analytic model was constructed, using data
from various sources, to replicate the process of a patient receiving
high-dose chemotherapy proceeding through stem cell mobilization,
apheresis, and transplant (ASCT). Data from the Washington
University site of the Plerixafor Phase III study were used to model
stem cell mobilization and apheresis (n 5 20). The probability of
mortality post-ASCT and utility values were taken from the litera-
ture. Medicare allowable costs were used. Microsimulation was
used to estimate the incremental cost-utility ratio (ICUR) from a so-
cietal perspective, with the patient’s remaining lifetime as the time
horizon.
Results: 100% (10/10) receiving P1G for stem cell mobilization
proceeded to ASCT, versus only 70% (7/10) of those receiving
G. Patients who did not proceed to transplant were assumed to
not contribute any cost or QALYs to the final model result. The ex-
pected lifetime cost of care for DLBCL for a person receiving P1G
was $25,567 more than one receiving G, and also accumulated 1.74more quality adjusted life years (QALYs) for an ICUR of $14,735/
QALY, because of the greater probability of undergoing transplant.
This is under the willingness to pay of $50,000/QALY accepted in
many industrialized nations. Sensitivity analyses revealed that this
$50,000/QALY standard was met so long as the probability of
transplant was greater than 77% in the G1P arm.
Conclusion:The use of plerixafor plus G-CSF for stem cell mo-
bilization for ASCT in patients with DLBCL will likely meet
most accepted standards of cost-effectiveness. This economic
benefit is largely the result of the effectiveness of the P1G reg-
imen in insuring that patients achieve sufficient cell counts prior
to ASCT.
Table 1. Plerixafor Plus G-CSF Costs and QALY’s
IncrementalStrategyTotal
Cost ($)Incremental
Cost ($)Total
Effectiveness
(QALY’s)*Incremental
Effectiveness
(QALY’s)*Cost-Effectiveness
Ratio (Cost /
QALY’s)*G-CSF Alone 67508 5.06Plerixafor
and G-CSF93076 25567 6.80 1.74 14735*Quality Adjusted LIfe Years125
A PHASE 1 STUDY OF BENDAMUSTINE AND MELPHALAN CONDITIONING
FOR AUTOLOGOUS STEM CELL TRANSPLANT IN MULTIPLE MYELOMA
Mark, T.M., Niesvizky, R., Gergis, U., Pearse, R.N., Mayer, S.,
Feldman, E.J., Shore, T.B. Weill Cornell Medical College, New York, NY
Background: Given data showing efficacy of bendamustine in
treating multiple myeloma (MM), we hypothesized that the addi-
tion of bendamustine to autologous stem cell transplant (ASCT)
conditioning would enhance response without significant toxicity
change. We now report the results of the first 4 cohorts of a phase
1 study of bendamustine 1 melphalan conditioning ASCT in
MM.
Methods: Fifteen patients were enrolled onto a 313 phase 1 study of
bendamustine added to melphalan 200mg/m2 split on subsequent
days. Bendamustine was given at the following dose levels on the in-
dicated days of melphalan: 1) 30 mg/m2 given on day 2; 2) 60 mg/m2
on day 2; 3) 90 mg/m2 on day 2; 4) 60mg/m2 on days 1 and 2. Stem
cell infusion of. 2 million 106 CD341 cells/kg was performed at
24-48 hours after the final dose of melphalan. All received G-CSF
with standard supportive care until engraftment, defined as absolute
neutrophil count . 500/ml and a platelet count . 20,000/ml with-
out transfusion. Bonemarrow biopsy and skeletal imagingwere prior
to and 100 days after ASCT to assess baseline and post-ASCT dis-
ease status. MM assessment was done monthly to assess disease re-
sponse as per accepted criteria.
Results: Fifteen patients completed ASCT over 4 cohorts: 3 in
dose level 1, 6 at dose level 2, and 3 each in dose levels 3 and 4.
Median time(range) to wbc engraftment and platelet engraftment
was 11 (9-13) days and 12 (11-27) days, respectively. No trans-
plant-related deaths occurred. Other than one patient with respira-
tory decompensation in the setting of neutropenic fever cohort 2 (a
dose limiting toxicity-DLT), only Grade 1 ASCT-associated toxic-
ity was seen: stomatitis in 8 (57%), diarrhea in 2 (14%), palpita-
tions / sinus tachycardia in 5 (36%), rash in 1 (7%), steroid-
psychosis in 1 (7%), and mild dyspnea in 1 (7%). Seven patients
(50%) had fever prior to wbc engraftment, with bacteremia in 3
(21%) and fungal infection in 1 (7%). At present, there are 11
evaluable MM responses at . 100 days post-ASCT. Three patients
(27%) died from MM, all beyond 100 days post-ASCT. In the
other 8, Day 100 response was complete remission in 6 (55%),
very good partial remission in 1 (9%), and minimal response in 1
(9%).
Summary: Bendamustine added to ASCT conditioning inMMdose
not exacerbate expected toxicities. TheMTDof bendamustine is still
unknown. The high complete remission rate, the best surrogate for
survival in MM, suggests a highly active regimen that should be ex-
plored.
